The role of transmembrane domain six (TMD6) of the angiotensin II type 1 receptor, which is predicted to undergo conformational changes after agonist binding, was investigated using the substituted-cysteine accessibility method. Each residue in the Lys240 -Leu265 fragment was mutated, one at a time, to a cysteine. The resulting mutants were expressed in COS-7 cells, which were subsequently treated with the charged sulfhydrylspecific alkylating agent methanethiosulfonate-ethylammonium (MTSEA). This treatment led to a significant reduction in binding Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
the wild-type receptor, it is assumed that the structure of the mutant receptor, especially around the binding site, is similar to that of wild-type and therefore that the substituted cysteine lies in an orientation similar to that of the wild-type residue. In TMDs, the sulfhydryl of a cysteine oriented toward the binding-site pocket should react more quickly with a positively charged sulfhydryl reagent such as methanethiosulfonate-ethylammonium (MTSEA) than sulfhydryls facing the interior of the protein or the lipid bilayer.
Two criteria are used to determine whether engineered cysteines are positioned at the surface of the binding-site pocket: 1) the reaction with MTSEA alters binding irreversibly and 2) the reaction is retarded by the presence of ligand. We previously used this approach to identify residues in TMD7 and TMD3 that line the surface of the binding-site pocket in the wild-type AT 1 receptor and in the constitutively active N111G-AT 1 receptor (Boucard et ]AngII (specific radioactivity, ϳ1500 Ci/mmol) was prepared using Iodo-GEN (Perbio Science, Erembodegem, Belgium) according to the method of Fraker and Speck (1978) and as reported previously (Guillemette and Escher, 1983) .
Materials and Methods

Materials
Numbering of Residues in TMD6. Residues in TMD6 of the human AT 1 receptor were given two numbering schemes. First, residues were numbered according to their positions in the human AT 1 receptor sequence. Second, residues were also indexed according to their positions relative to the most conserved residue in the TMD in which they are located (Ballesteros and Weinstein, 1995) . By definition, the most conserved residue was assigned index position "50." For example, in TMD6, Pro255 is the most conserved residue and was designated Pro255 (6.50) ; Ile254 (6.49) and His256 (6.51) are the adjacent N-and C-terminal residues, respectively, of Pro255 (6.50) . This indexing scheme simplifies the identification of aligned residues in different GPCRs of the same class.
Oligodeoxynucleotide Site-Directed Mutagenesis. Site-directed mutagenesis was performed on the wild-type AT 1 receptor using the overlap PCR method (Expand High-Fidelity PCR System; Roche Diagnostics, Laval, QC, Canada). In brief, forward and reverse oligonucleotides were constructed to introduce cysteine mutations between Lys240 (6.35) and Leu265 (6.60) . PCR products were subcloned into the HindIII-XbaI sites of the mammalian expression vector pcDNA3.1. Site-directed mutations were then confirmed by automated DNA sequencing by aligning the AT 1 sequence with multiAlin (Corpet, 1988) .
Cell Culture and Transfections. COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 2 mM Lglutamine and 10% (v/v) fetal bovine serum. The cells were seeded into 100-mm culture dishes at a density of 2 ϫ 10 6 cells/dish. When cells were at ϳ90% confluence, they were transfected with 4 g of plasmid DNA and 15 l of LipofectAmine2000. After 24 h, transfected cells were trypsinized, distributed into 12-well plates, and grown for an additional 24 h in complete DMEM containing 100 IU/ml penicillin and 100 g/ml streptomycin before MTSEA treatment and binding assay were performed.
Binding Experiments COS-7 cells were grown for 36 h after transfection in 100-mm culture dishes, washed once with phosphatebuffered saline (PBS), and subjected to one freeze-thaw cycle. Broken cells were then gently scraped into washing buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl 2 ), centrifuged at 2500 g for 15 min at 4°C, and resuspended in binding buffer (25 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM MgCl 2 , 0.1% BSA, 0.01% bacitracin, 0.01% soybean trypsin inhibitor Bound radioactivity was separated from free ligand by filtration through GF/C filters presoaked for at least 3 h in binding buffer. Receptor-bound radioactivity was evaluated by ␥ counting.
Intracellular IP Accumulation Measurement. Inositol phosphate accumulation was determined as described previously (Lanctôt et al., 1999). In brief, basal production of inositol phosphates was measured after this modification: COS-7 cells were seeded in six-well plates, transfected, and labeled for 16 h in serum-free, inositol free M199 containing 10 Ci/ml [myo- Effect of Extracellularly Added MTSEA on the Binding Properties of Mutant Receptors. To verify whether the reporter cysteines introduced into TMD6 were oriented toward the binding pocket, mutant receptors were treated with concentrations of MTSEA varying between 0.5 and 6 mM. We had previously verified whether the wild-type AT 1 receptor, which contains 10 endogenous cysteines (Fig. 1) , was sensitive to the MTSEA treatment and found that the various concentrations of MTSEA had very little effect (no more than a 25% reduction at high MTSEA concentrations) on the binding properties of the wild-type AT 1 receptor, indicating that the endogenous cysteines made a relatively small contribution to the binding-site pocket (Boucard et al., 2003) .
When the AT 1 mutant receptors were treated with the alkylating agent, we found that a 3-min treatment with 2 mM MTSEA (Fig. 3) 
Discussion
The rationale of this study, which relied on SCAM analysis, was to gain an insight into the orientation of TMD6 of the AT 1 receptor by identifying the residues accessible to MTSEA within the binding site pocket. Mapping these residues in the ground state receptor and the constitutively active N111G background allowed us to measure relative changes in the position of certain residues, thus providing valuable information with which to infer a structural change underlying AT 1 receptor activation. AngII protected all the residues tested in the protection assay, thus supporting the notion that these specific residues within TMD6 are located in the binding pocket. Although the A244C (6.39) mutant did show sensitivity, we did not consider this residue to be in the binding pocket because 1) it was at the limit of detectability only at 2 mM MTSEA in our assay conditions and 2) it is not on the same helical face as the other positive residues discussed above.
Our finding that these residues were located in the binding pocket of the AT 1 receptor is in accordance with the current models proposed for bovine rhodopsin (Palczewski et phan residue found in many (40%; see Table 3 ) class A receptors, is located in the binding pocket. The present SCAM study identified Trp253 (6.48) in the N111G-AT 1 receptor background but not in the ground state, which may be explained by the toggle switch mechanism (see below). In light of these results, the orientation of conserved positions within the ligand-binding pocket may be a common feature of TMD6 of class A GPCRs.
To further investigate the mechanism by which the AT 1 receptor undergoes structural changes during the transition from its inactive to its active state, we took advantage of the constitutively active N111G-AT 1 receptor. It is believed that the isomerization of conformers toward the active state, which involves TMD movement, is stabilized by the binding of an agonist, and may be mimicked in part by the constitutively active receptor (Gether and Kobilka, 1998; Seifert and Wenzel-Seifert, 2002 The divergence in the sensitive Cys-substituted residues between the wild-type AT 1 receptor and the N111G-AT 1 receptor (Fig. 7) suggests that the accessibility of residues in TMD6 and their spatial proximity within the binding pocket were altered as a result of the single substitution of Asn111 for Gly in TMD3. Our results point to a significant structural change during the process of activation of the receptor. (Shi et al., 2002) . In rhodopsin, this conserved residue, which is found in numerous class A GPCRs, undergoes a conformational transition when the receptor goes from the ground state to the active state. This is due to a disruption of hydrogen bond networks formed through Asp (2.50) , Asn (7.45) , and water molecules, which shifts the orientation of Trp253 (6.48) from pointing toward TMD7 to pointing toward TMD5 upon receptor activation (Ruprecht et al., 2004) . Thus, the nonreactivity of W253C in the basal state could be due to similar intramolecular interactions of the introduced cysteine with residues of other TMDs, rendering it inaccessible to MTSEA, whereas in the N111G constitutively active receptor background, reorientation of the side chain of this residue would make it more susceptible to alkylation by MTSEA.
We therefore propose that the middle portion of TMD6 does not move extensively during the activation of the AT 1 receptor. In the N111G-mutant background, F261C (6.56) , which is near the top of TMD6, became MTSEA-sensitive. This residue is located at the periphery of the helical face formed by (6.59) , T260C (6.55) , H256C (6.51) , and F249C (6.44) residues identified in the ground state (see Fig. 7 ). Such a gain in sensitivity may signify that, upon activation, the top of TMD6 may rotate clockwise, thereby enabling F261C (6.56) to enter the binding pocket and be alkylated. The significant reduction of sensitivity of V264C (6.59) to MTSEA in the N111G constitutively active receptor background compared with the wild-type basal state also suggests that, although it remains in the binding pocket, both the position/orientation of V264C (6.59) and the top of TMD6 change in the activation process.
For residues located deeper in TMD6, we observed that Phe249 (6.44) was highly sensitive in the ground state and became nonsensitive in the N111G background. One possibility is that along with the rotation of the top of TMD6, the bottom of the helix may independently undergo a pivoting action away from the lower part of the pocket. Another simpler alternative to explain our results could be that, during the process of AT 1 receptor activation, TMD6 undergoes integral pivoting (without additional movements in the top or bottom of the TMD), bringing the top of the TMD toward the binding pocket and pushing the bottom away from the binding pocket. This straightforward pivoting movement would expose Phe261 (6.56) to the binding pocket and extrude Phe249 (6.44) out of the binding pocket (Fig. 8) . This explanation would go along with the four proposed simple but varied types of movements (pivoting, rotation, translation, piston movement) that TMD ␣-helices can undergo in a lipid bilayer (Matthews et al., 2006) .
In conclusion, our data comparing the ground state to the activated state of the AT 1 receptor point toward a pivoting movement of TMD6 that exposes Phe261 (6.56) and alters the exposure of Val264 (6.59) to a water-accessible crevice. The outward movement of the bottom of TMD6 would shift Phe249 (6.44) away from the binding pocket. This movement would contribute to the structural relaxation of the activated receptor and would facilitate the flexibility of the third cytoplasmic loop, enabling binding and/or activation of the cognate G protein as recently suggested for rhodopsin (Salom et al., 2006) . The pivoting movement of TMD6 upon activation of the AT 1 receptor is reminiscent of the inward movement of the extracellular segment and outward movement of the intracellular segment of TMD6 recently observed with the ␤ 2 -adrenergic receptor (Elling et al., 2006 ). This particular movement may thus be a structural feature common to numerous rhodopsin-like GPCRs. 
